Get the Stockscreener App
198.71
0.84%
-1.69
After Hours:
199.65
0.94
+0.47%
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $198.71, with a volume of 4.06M.
It is down -0.84% in the last 24 hours and down -12.78% over the past month.
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
See More
Previous Close:
$200.40
Open:
$199.5
24h Volume:
4.06M
Relative Volume:
1.95
Market Cap:
$59.07B
Revenue:
$20.64B
Net Income/Loss:
$1.73B
P/E Ratio:
33.01
EPS:
6.02
Net Cash Flow:
$2.94B
1W Performance:
-0.21%
1M Performance:
-12.78%
6M Performance:
-17.32%
1Y Performance:
-14.43%
1-Day Range:
$198.40
$201.28
1-Week Range:
$196.57
$206.78
52-Week Range:
$193.03
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-18-22 | Resumed | Raymond James | Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-01-20 | Resumed | Goldman | Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
| Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-07-18 | Initiated | Deutsche Bank | Buy |
| Oct-16-18 | Initiated | Barclays | Equal Weight |
| Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Jan-19-18 | Resumed | BofA/Merrill | Buy |
| Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
| Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
Is Becton, Dickinson and Company (BDX) the Best Dividend Monarch to Invest in Now? - Insider Monkey
Is Becton Dickinson Gaining or Losing Market Support? - Benzinga
Global In-Vitro Diagnostics Market Predicted to Surpass the USD 90 Billion Mark by 2032 | DelveInsight - GlobeNewswire Inc.
Becton, Dickinson and Co. : Leading Industry Analyst Amit Bhalla Joins BD as Vice President, Global Strategy and Development - MarketScreener
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports - MSN
Barclays Has Lowered Expectations for Becton, Dickinson and Company (NYSE:BDX) Stock Price - MarketBeat
Retired truck driver contends emissions from ethylene oxide caused his cancer - AJC.com
BD to acquire Bard - The Covington News
Becton, Dickinson and Co. : BD Appoints Christopher Reidy as Chief Financial Officer - MarketScreener
Becton Dickinson EVP Michael Garrison sells $94,497 in stock - Investing.com Australia
Becton Dickinson EVP Michael Garrison sells $94,497 in stock By Investing.com - Investing.com Canada
Becton Dickinson and : BD Receives FDA 510(k) Clearance for Advanced Microbiology Solution - MarketScreener
Becton Dickinson's SWOT analysis: med tech giant's stock poised for growth - Investing.com
BD Seeks Potential Buyers for Life Sciences Business Division - Yahoo Finance
Citigroup Adjusts Becton Dickinson and Co. Price Target to $270 From $275, Maintains Buy Rating - MarketScreener
Becton, Dickinson Becomes Oversold - Nasdaq
Should You be Confident in Becton, Dickinson and Company’s (BDX) Ability to Deliver Long-Term Returns? - Yahoo
BD reports pay increases for some execs, decreases for others - Medical Design & Outsourcing
BD to Announce Financial Results for its Second Quarter of Fiscal 2025 - Quantisnow
Vascular Access Device Market Growth is Driven by Ongoing Research and Development in the Industry, Key Players -Becton, Dickinson and Company, - Global Banking | Finance | Review
Report: BD is in talks with competitors to sell Life Sciences biz - MassDevice
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports - MarketScreener
Becton Dickinson in talks to divest life sciences unit, FT reports - MarketScreener
Becton Dickinson In Talks With Rivals Over Divesting Life Sciences Unit- FT - MarketScreener
Becton Dickinson in talks with rivals over divesting life sciences unit - Financial Times
BD Named One of America's Most Innovative Companies by Fortune - Quantisnow
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline - Seeking Alpha
Here’s What Positions Becton, Dickinson and Company (BDX) Favorably in the Health Care Sector - Yahoo Finance
BD Names Gregory J. Hayes to Board of Directors :: Becton, Dickinson and Company (BDX) - Becton Dickinson
BD Names Gregory J. Hayes to Board of Directors - Quantisnow
BD Names Gregory J. Hayes to Board of Directors – Company Announcement - Financial Times
Goldman Sachs Adjusts PT on Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating - Marketscreener.com
Goldman Sachs Adjusts PT to Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating - MarketScreener
Was Jim Cramer Right About Becton, Dickinson and Company (BDX)? - Insider Monkey
Insider Sell: Richard Byrd Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus.com
FDA tags Becton, Dickinson and Company infusion software recall as Class I - Yahoo Finance
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Becton Dickinson and : BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance - MarketScreener
Becton, Dickinson Treats First Breast Revision Patient in GalaFlex Lite Scaffold Trial -March 20, 2025 at 07:56 am EDT - MarketScreener
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery - Quantisnow
Becton, Dickinson and Company Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE? Scaffold in Breast Implant Revision Surgery - Marketscreener.com
Correction: Software for Alaris Systems Manager and CCE Adapter - fda.gov
Becton Dickinson EVP Richard Byrd sells $105,570 in stock By Investing.com - Investing.com Australia
Becton Dickinson EVP Richard Byrd sells $105,570 in stock - Investing.com
SEC Form 144 filed by Becton Dickinson and Company - Quantisnow
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):